Valuation Charles River Laboratories International, Inc. Berne S.E.
Stocks
RV6
US1598641074
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - CHF | -.--% |
|
-.--% | - |
Company Valuation: Charles River Laboratories International, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 18,941 | 11,138 | 12,252 | 9,520 | 10,023 | 9,032 | - | - |
| Change | - | -41.2% | 10% | -22.3% | 5.29% | -9.89% | - | - |
| Enterprise Value (EV) 1 | 21,366 | 13,616 | 14,622 | 11,565 | 11,946 | 10,844 | 10,500 | 10,123 |
| Change | - | -36.28% | 7.39% | -20.91% | 3.29% | -9.22% | -3.18% | -3.59% |
| P/E Ratio | 49.4x | 23.1x | 25.9x | 931x | -70x | 30.6x | 20.4x | 18.6x |
| PBR | 7.45x | 3.75x | 3.41x | 2.75x | 3.17x | 2.74x | 2.49x | 2.26x |
| PEG | - | 0.9x | -9.44x | -9.5x | 0x | -0x | 0.4x | 1.97x |
| Capitalization / Revenue | 5.35x | 2.8x | 2.97x | 2.35x | 2.5x | 2.34x | 2.3x | 2.2x |
| EV / Revenue | 6.04x | 3.42x | 3.54x | 2.86x | 2.98x | 2.81x | 2.68x | 2.47x |
| EV / EBITDA | 24.3x | 13.7x | 14.4x | 11.6x | 12.3x | 11x | 10x | 9.11x |
| EV / EBIT | 28.8x | 16.3x | 17.4x | 14.3x | 15x | 13.3x | 11.9x | 10.7x |
| EV / FCF | 40.2x | 46.2x | 40x | 23.1x | 23x | 31.2x | 26.7x | 42.3x |
| FCF Yield | 2.49% | 2.17% | 2.5% | 4.34% | 4.34% | 3.21% | 3.74% | 2.37% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 7.6 | 9.48 | 9.22 | 0.2 | -2.91 | 6.135 | 9.2 | 10.07 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 3,540 | 3,976 | 4,129 | 4,050 | 4,015 | 3,855 | 3,924 | 4,105 |
| EBITDA 1 | 879.5 | 990.9 | 1,013 | 996.1 | 971.5 | 986.4 | 1,046 | 1,111 |
| EBIT 1 | 742.1 | 834 | 838.8 | 805.9 | 793.9 | 813.2 | 881 | 947.2 |
| Net income 1 | 391 | 486.2 | 474.6 | 10.3 | -144.3 | 285.1 | 417.2 | 449 |
| Net Debt 1 | 2,425 | 2,477 | 2,370 | 2,046 | 1,923 | 1,812 | 1,468 | 1,091 |
| Reference price 2 | 375.34 | 218.92 | 238.84 | 186.16 | 203.66 | 187.51 | 187.51 | 187.51 |
| Nbr of stocks (in thousands) | 50,464 | 50,879 | 51,297 | 51,136 | 49,215 | 48,168 | - | - |
| Announcement Date | 16/02/22 | 22/02/23 | 14/02/24 | 19/02/25 | 18/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E Ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 29.71x | 5.27x | 16.33x | 1.11% | 42.96B | ||
| -18.77x | 275.88x | -16.99x | -.--% | 31.73B | ||
| 22.03x | 2.54x | 10.97x | -.--% | 30.22B | ||
| 38.83x | 3.84x | 24.59x | -.--% | 28.94B | ||
| 28.09x | 7.25x | 18.65x | 0.42% | 23.87B | ||
| 27.88x | 4.48x | 20.38x | -.--% | 13.57B | ||
| 22.34x | 1.93x | 8.51x | 1.19% | 12.96B | ||
| -20.61x | 13.45x | -20.03x | -.--% | 12.2B | ||
| Average | 16.19x | 39.33x | 7.80x | 0.34% | 24.55B | |
| Weighted average by Cap. | 18.11x | 48.82x | 9.13x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CRL Stock
- RV6 Stock
- Valuation Charles River Laboratories International, Inc.
Select your edition
All financial news and data tailored to specific country editions
















